mRNA-1982
RNA therapy
ModernamRNA-1982 is one of 9 biologic programs targeting Lyme disease. It is currently in development.
1
Indications
1
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Lyme Disease
#DrugCompanyPhaseTrials
1Achromycin V
WWyeth-Lederle Vaccines
Approved
Rocephin
CConrado Roberto Hoffmann Filho
Phase 3
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Antabuse
TevaPhase 2
Antibiotics
MMelinta Therapeutics, Inc.
Phase 3
VLA15
PfizerPhase 3
Psilocybin
COMPASS PathwaysPhase 1
Ceftriaxone Treatment
NNantes University Hospital
Phase 2
mRNA-1982
ModernaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for mRNA-1982. EMBL-EBI & Wellcome Sanger Institute.
- [4]